Tiziana Life Sciences Ltd
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tiziana Life Sciences Ltd (Nasdaq: TLSA), a clinical-stage biotechnology company headquartered in London, United Kingdom and founded in 1998, develops breakthrough immunomodulation therapies via innovative nasal delivery technologies for neurodegenerative, neuroinflammatory and autoimmune diseases; its lead candidate is intranasal Foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody in Phase 2a trials for non-active secondary progressive multiple sclerosis (na-SPMS; dosing began 4Q 2023), multiple system atrophy (MSA; dosing began August 2025), amyotrophic lateral sclerosis (ALS; Phase 2 to begin 2H 2025 with ALS Association grant), mild Alzheimer's disease (Phase 2 to begin 2H 2025) and moderate Alzheimer's (expanded access dosing began December 2024), with investigational new drug application planned for long COVID and preclinical exploration in early onset type 1 diabetes mellitus and intracerebral hemorrhage; it also advances TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody targeting inflammatory and oncology indications including lung diseases via dual inhibition of membrane-bound and soluble IL-6R, and evaluates milciclib in combination with gemcitabine for KRAS-positive non-small cell lung cancer; prior formulations of Foralumab include well-tolerated oral and intravenous routes tested in Phase 1/2 for Crohn's disease. In recent developments, Tiziana announced in December 2025 plans to spin out TZLS-501 and related assets into a separate publicly listed immunology-focused company to unlock value and sharpen strategic focus amid heightened IL-6 pathway interest following Novartis' $1.4 billion acquisition of Tourmaline Bio, subject to shareholder approval; CEO Ivor Elrifi purchased 193,848 common shares at $1.65 each in September 2025 signaling management confidence; the company secured a U.S. Department of Defense grant in September 2025 to accelerate intranasal Foralumab and its expanded access program for na-SPMS dosed 14 patients with observed stability or improvement; Executive Chairman Gabriele Cerrone increased insider ownership to 36.28% through recent purchases. Tiziana operates globally with clinical trials across multiple sites, supported by extensive patents through 2040 on compositions, formulations and indications, and maintains a lean team of nine employees focused on alternative immunotherapy routes to enhance efficacy, safety and tolerability over intravenous delivery.
Company News
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
Dow climbs as stocks rebound on earnings, falling Treasury yields
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
Gemini Pro delay leaves Google with an empty flagship tier
Tiziana Life Sciences announces CEO share purchase
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
Qualcomm raises long-term targets as analysts highlight data center, edge AI opportunities